Aristotle Atlantic Partners’s Guardant Health GH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $66.4M | Sell |
442,816
-2,714
| -0.6% | -$295K | 2.75% | 10 |
|
|
2026
Q1 | $41.2M | Sell |
445,530
-48,856
| -10% | -$4.91M | 1.93% | 15 |
|
|
2025
Q4 | $50.5M | Sell |
494,386
-429,348
| -46% | -$38.4M | 2.31% | 11 |
|
|
2025
Q3 | $57.7M | Sell |
923,734
-8,222
| -0.9% | -$447K | 1.67% | 15 |
|
|
2025
Q2 | $48.5M | Sell |
931,956
-32,565
| -3% | -$1.45M | 1.48% | 19 |
|
|
2025
Q1 | $41.1M | Buy |
964,521
+112,526
| +13% | +$4.85M | 1.39% | 23 |
|
|
2024
Q4 | $26M | Sell |
851,995
-41,513
| -5% | -$1.17M | 0.82% | 32 |
|
|
2024
Q3 | $20.5M | Buy |
893,508
+144,311
| +19% | +$4.08M | 0.64% | 41 |
|
|
2024
Q2 | $21.6M | Sell |
749,197
-57,698
| -7% | -$1.34M | 0.7% | 39 |
|
|
2024
Q1 | $16.6M | Sell |
806,895
-30,050
| -4% | -$644K | 0.54% | 53 |
|
|
2023
Q4 | $22.6M | Buy |
836,945
+2,849
| +0.3% | +$74.7K | 0.8% | 43 |
|
|
2023
Q3 | $24.7M | Sell |
834,096
-23,472
| -3% | -$825K | 0.99% | 36 |
|
|
2023
Q2 | $30.7M | Buy |
857,568
+237,074
| +38% | +$6.81M | 1.16% | 27 |
|
|
2023
Q1 | $14.5M | Buy |
620,494
+1,723
| +0.3% | +$49.2K | 0.75% | 47 |
|
|
2022
Q4 | $16.8M | Buy |
618,771
+237,627
| +62% | +$10.9M | 0.94% | 39 |
|
|
2022
Q3 | $20.5M | Buy |
381,144
+172,050
| +82% | +$8.83M | 1.25% | 25 |
|
|
2022
Q2 | $8.44M | Buy |
209,094
+3,894
| +2% | +$193K | 0.65% | 42 |
|
|
2022
Q1 | $13.6M | Buy |
205,200
+2,847
| +1% | +$195K | 0.84% | 33 |
|
|
2021
Q4 | $20.2M | Buy |
202,353
+7,423
| +4% | +$768K | 1.17% | 29 |
|
|
2021
Q3 | $24.4M | Buy |
194,930
+2,223
| +1% | +$264K | 1.61% | 24 |
|
|
2021
Q2 | $23.9M | Buy |
192,707
+1,839
| +1% | +$247K | 1.58% | 26 |
|
|
2021
Q1 | $29.1M | Buy |
190,868
+3,462
| +2% | +$523K | 2.13% | 15 |
|
|
2020
Q4 | $24.2M | Buy |
187,406
+2,749
| +1% | +$316K | 1.86% | 23 |
|
|
2020
Q3 | $20.6M | Buy |
184,657
+1,560
| +0.9% | +$143K | 1.82% | 23 |
|
|
2020
Q2 | $14.9M | Buy |
183,097
+35,855
| +24% | +$2.89M | 1.43% | 28 |
|
|
2020
Q1 | $10.2M | Buy |
147,242
+4,058
| +3% | +$311K | 1.57% | 28 |
|
|
2019
Q4 | $11.2M | Buy |
143,184
+100,167
| +233% | +$7.22M | 1.43% | 27 |
|
|
2019
Q3 | $2.75M | Buy |
43,017
+1,011
| +2% | +$89.1K | 0.79% | 26 |
|
|
2019
Q2 | $3.63M | Buy |
42,006
+1,851
| +5% | +$141K | 1.05% | 20 |
|
|
2019
Q1 | $3.08M | Buy |
+40,155
| New | +$2.23M | 0.94% | 23 |
|
Other funds holding GH
DTC
Aristotle Atlantic Partners's GH Position: Q2 2026 in Review
Aristotle Atlantic Partners reduced its Guardant Health (GH) stake by 0.61% in Q2 2026, selling an estimated $295K and leaving 442,816 shares worth $66.4M. The position accounts for 2.75% of the portfolio, ranked #10.
Aristotle Atlantic Partners first reported a position in GH in Q1 2019 and has held it in 30 quarters since. 597 funds tracked by Wall St. Rank hold GH as of Q2 2026.
- Aristotle Atlantic Partners held 442,816 shares of Guardant Health worth $66.4M as of Q2 2026.
- Aristotle Atlantic Partners sold 2,714 Guardant Health shares in Q2 2026, an estimated $295K.
- Guardant Health made up 2.75% of Aristotle Atlantic Partners's portfolio in Q2 2026, its #10 holding.
- Aristotle Atlantic Partners first reported a position in Guardant Health in Q1 2019 and has held it in 30 quarters since.
- 597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.
Based on Aristotle Atlantic Partners's 13F filing for Q2 2026, filed 14 Aug 2026.